Stromal annexin A2 immunostaining in the invasive serous ovarian carcinomas (stage I to IV) was significantly increased compared with normal ovaries, serous cystadenomas, or serous borderline tumors (P < 0.0001). Here, ANXA2 is linked to ovarian serous carcinoma.